G-treeBNT to receive $7.28 million to expand international development of RGN-259/GBT-201

RegeneRx Biopharmaceuticals, Inc. has been notified that its joint venture partner and licensee, G-treeBNT Co. Ltd., will receive $7.28 million USD to expand international development of its product candidate, RGN-259 (designated GBT-201).



from The Medical News http://ift.tt/1BZ7dVe